Health Tidings Mergers & AcquisitionsYarrow Bioscience Initiates Phase 2 Trial of Anti-TSHR Antibody YB-101 for ... Yarrow Bioscience Initiates Phase 2 Trial of Anti-TSHR Antibody YB-101 for ... Read Post »
Health TidingsAmgen Defends TAVNEOS With New FDA Submission to Prevent Proposed U.S. Mark... Amgen Defends TAVNEOS With New FDA Submission to Prevent Proposed U.S. Mark... Read Post »
GenericsFDA Approves First OTC Tylenol with Naproxen for 12-Hour Pain Relief FDA Approves First OTC Tylenol with Naproxen for 12-Hour Pain Relief Read Post »
Health TidingsHEMGENIX Achieves 100 Commercial Treatments for Adults with Hemophilia B HEMGENIX Achieves 100 Commercial Treatments for Adults with Hemophilia B Read Post »
Health TidingsFDA Advisory Committee Recommends Four Peptides for 503A Compounding List D... FDA Advisory Committee Recommends Four Peptides for 503A Compounding List D... Read Post »
Health TidingsMerck Launches Global Access Plan for Once-Monthly HIV Prevention Pill Alim... Merck Launches Global Access Plan for Once-Monthly HIV Prevention Pill Alim... Read Post »
Health TidingsNanvuranlat Enters First-Line BTC Trial With New 46-Hour Infusion Strategy Nanvuranlat Enters First-Line BTC Trial With New 46-Hour Infusion Strategy Read Post »
Health TidingsFDA Grants Fast Track Status to Oral Orexin 2 Agonist Lu AH69593 for Narcol... FDA Grants Fast Track Status to Oral Orexin 2 Agonist Lu AH69593 for Narcol... Read Post »
Health TidingsInsilico Advances AI-Discovered Non-Opioid Pain Candidate ISM9528 Toward Cl... Insilico Advances AI-Discovered Non-Opioid Pain Candidate ISM9528 Toward Cl... Read Post »
Health TidingsTecvayli Plus Talvey Significantly Improves Survival in Phase 3 Multiple My... Tecvayli Plus Talvey Significantly Improves Survival in Phase 3 Multiple My... Read Post »
Health TidingsCrystalys Therapeutics Raises $130 Million to Advance Phase 3 Development o... Crystalys Therapeutics Raises $130 Million to Advance Phase 3 Development o... Read Post »
Health TidingsNHS England Introduces Fampridine for Walking Difficulties in Multiple Scle... NHS England Introduces Fampridine for Walking Difficulties in Multiple Scle... Read Post »
Health TidingsPositive TALAPRO-3 Data Earn FDA Priority Review for TALZENNA Plus XTANDI Positive TALAPRO-3 Data Earn FDA Priority Review for TALZENNA Plus XTANDI Read Post »
Health TidingsBridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 Read Post »
Health TidingsFDA Grants Orphan Drug Status to Affinia’s AFTX-201 for BAG3-Associat... FDA Grants Orphan Drug Status to Affinia’s AFTX-201 for BAG3-Associat... Read Post »
Health TidingsRadiopharm’s RAD101 PET Imaging Meets Phase 2b Primary Endpoint in Re... Radiopharm’s RAD101 PET Imaging Meets Phase 2b Primary Endpoint in Re... Read Post »
Health TidingsPeer-Reviewed Phase 1 Data Support TLX591-Tx as a Differentiated PSMA-Targe... Peer-Reviewed Phase 1 Data Support TLX591-Tx as a Differentiated PSMA-Targe... Read Post »
Health TidingsRibo’s Vortosiran Cuts Factor XI Activity by 92% in Phase 2a Coronary... Ribo’s Vortosiran Cuts Factor XI Activity by 92% in Phase 2a Coronary... Read Post »
GenericsFDA Expands Glenmark’s RYALTRIS Use for Seasonal Allergic Rhinitis in... FDA Expands Glenmark’s RYALTRIS Use for Seasonal Allergic Rhinitis in... Read Post »
Health TidingsIslatravir/Lenacapavir Maintains Virological Suppression Through 48 Weeks i... Islatravir/Lenacapavir Maintains Virological Suppression Through 48 Weeks i... Read Post »
Health TidingsTempest Advances TPST-4003 Toward First Clinical Evaluation of In Vivo CAR-... Tempest Advances TPST-4003 Toward First Clinical Evaluation of In Vivo CAR-... Read Post »
Health TidingsIMUNON Reports Positive Phase 2 Translational Data Supporting IMNN-001 in A... IMUNON Reports Positive Phase 2 Translational Data Supporting IMNN-001 in A... Read Post »
Medical DevicesEnvoy Medical Completes Three-Month Milestone in Acclaim Cochlear Implant T... Envoy Medical Completes Three-Month Milestone in Acclaim Cochlear Implant T... Read Post »
Health TidingsNOUS-209 Re-Treatment Boosts Durable T-Cell Responses in Lynch Syndrome NOUS-209 Re-Treatment Boosts Durable T-Cell Responses in Lynch Syndrome Read Post »
Health TidingsPhanes Advances Spevatamig-KYTRUDA in First-Line Biliary Tract Cancer with ... Phanes Advances Spevatamig-KYTRUDA in First-Line Biliary Tract Cancer with ... Read Post »
Health TidingsFDA Grants Fast Track Designation to Oncolytics’s Pelareorep FDA Grants Fast Track Designation to Oncolytics’s Pelareorep Read Post »
Health Tidings Mergers & AcquisitionsHalozyme and Incyte Partner to Advance Subcutaneous INCA033989 for mutCALR-... Halozyme and Incyte Partner to Advance Subcutaneous INCA033989 for mutCALR-... Read Post »
Health TidingsFDA Grants Priority Review to Dyne’s z-Rostudirsen for DMD FDA Grants Priority Review to Dyne’s z-Rostudirsen for DMD Read Post »
Health TidingsNamodenoson Shows Durable Disease Control in Advanced Pancreatic Cancer Namodenoson Shows Durable Disease Control in Advanced Pancreatic Cancer Read Post »
Health TidingsDuvakitug Improves Clinical Remission in Ulcerative Colitis Trial Duvakitug Improves Clinical Remission in Ulcerative Colitis Trial Read Post »
Health TidingsSafusidenib Delivers Long-Term Benefit in Grade 2 IDH1-Mutant Glioma Safusidenib Delivers Long-Term Benefit in Grade 2 IDH1-Mutant Glioma Read Post »
Health TidingsDuvakitug Shows Positive Phase 2b Results in Crohn’s Disease Duvakitug Shows Positive Phase 2b Results in Crohn’s Disease Read Post »
Health TidingsEMA Accepts GSK’s Bexsero Single-Dose Booster Label Expansion EMA Accepts GSK’s Bexsero Single-Dose Booster Label Expansion Read Post »
Health TidingsPivotal Bexicaserin Trial Completes Randomization in Rare Childhood Epileps... Pivotal Bexicaserin Trial Completes Randomization in Rare Childhood Epileps... Read Post »
GenericsNATCO Pharma Secures Tentative US FDA Approval for Generic Olaparib Tablets NATCO Pharma Secures Tentative US FDA Approval for Generic Olaparib Tablets Read Post »
Health TidingsKamuvudine-8 Reduced Geographic Atrophy Progression by 54% in Phase 2 Study Kamuvudine-8 Reduced Geographic Atrophy Progression by 54% in Phase 2 Study Read Post »
Health TidingsInnoCare’s Soficitinib Meets Phase II Endpoint in Vitiligo InnoCare’s Soficitinib Meets Phase II Endpoint in Vitiligo Read Post »
GenericsAmneal Secures FDA Approval for Additional Iohexol Injection Presentations,... Amneal Secures FDA Approval for Additional Iohexol Injection Presentations,... Read Post »
Health TidingsCamurus CAM2029 NDA Accepted by FDA for Acromegaly Camurus CAM2029 NDA Accepted by FDA for Acromegaly Read Post »
Health TidingsShionogi’s Fetroja sNDA Accepted by FDA for Pediatric Hospital Pneumonia ... Shionogi’s Fetroja sNDA Accepted by FDA for Pediatric Hospital Pneumonia ... Read Post »
Health TidingsFabhalta Secures Full FDA Approval to Slow Kidney Function Decline in IgA N... Fabhalta Secures Full FDA Approval to Slow Kidney Function Decline in IgA N... Read Post »
Health TidingsDimerix Acquires Phase 2-Ready DMX-652 for Acute Kidney Injury Dimerix Acquires Phase 2-Ready DMX-652 for Acute Kidney Injury Read Post »
Health TidingsTrellis Raises $9M to Advance Calpurbatug Phase 2 in Prosthetic Joint Infec... Trellis Raises $9M to Advance Calpurbatug Phase 2 in Prosthetic Joint Infec... Read Post »
Health TidingsMedicus Advances Optimized Phase 2 Teverelix Trial After FDA Feedback Medicus Advances Optimized Phase 2 Teverelix Trial After FDA Feedback Read Post »
Health TidingsKalshi and AppliedXL Launch Prediction Markets for Clinical Trial Outcomes Kalshi and AppliedXL Launch Prediction Markets for Clinical Trial Outcomes Read Post »
ManufacturingGates MRI Taps GSK’s AS01E Adjuvant and Serum Institute of India̵... Gates MRI Taps GSK’s AS01E Adjuvant and Serum Institute of India̵... Read Post »
Health TidingsCOMP360 Phase 2 Analysis Supports Psilocybin Effects in PTSD COMP360 Phase 2 Analysis Supports Psilocybin Effects in PTSD Read Post »
Health Tidings Mergers & AcquisitionsChai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody ... Chai Discovery and argenx Partner to Accelerate AI-Driven De Novo Antibody ... Read Post »
Health Tidings Mergers & AcquisitionsLilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant Depre... Lilly Acquires AtaiBeckley to Advance BPL-003 for Treatment-Resistant Depre... Read Post »
Health TidingsEisai’s Lemborexant Marketing Application Accepted by EMA for Chronic Ins... Eisai’s Lemborexant Marketing Application Accepted by EMA for Chronic Ins... Read Post »
